RT Journal Article
SR Electronic
T1 Is Anticancer Drug Development Heading in the Right Direction?
JF Cancer Research
JO Cancer Res
FD American Association for Cancer Research
SP 1259
OP 1262
DO 10.1158/0008-5472.CAN-08-3786
VO 69
IS 4
A1 Hambley, Trevor W.
YR 2009
UL http://cancerres.aacrjournals.org/content/69/4/1259.abstract
AB The success of molecularly targeted agents, such as imatinib, has led to expectations of a new era in anticancer drug development, and to a greatly increased focus on targeting as a strategy. However, the number of successes to date is small, and recent results suggest that the success of imatinib, for instance, in treating chronic myelogenous leukemia and gastrointestinal stromal tumor may be the exception rather than the rule. Here, we argue that the search for new anticancer agents needs to continue on as many fronts as possible, and not be focused on one strategy alone. [Cancer Res 2009;69(4):1259–62]